A large real-world prospective study on the long-term effectiveness and safety of faricimab and “Port Delivery System with ranibizumab” (PDS), for nAMD or DME, is… Read More »Real-world data on treatment of AMD/DME patients with faricimab and port delivery system with ranibizumab will run to 2027 (“VOYAGER” ).
Ocugen Inc., (NASDAQ:OCGN), an ophthalmic biopharmaceutical company based in Malvern, Pennsylvania, has announced the completion of dosing in their second cohort of its Phase 1/2… Read More »Ocugen Inc completes dosing of a Phase 1/2 study for a modifier gene therapy to treat Stargardt disease.
Dear EURETINA Members, A very warm welcome to the May 27th, 2024 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue… Read More »May 27th, 2024 “EURETINA-Brief”© Issue No. 292
The expansion on the field of genetics and genomics is reflective to the changes of the average 6.4 years between each of the nine editions… Read More »Book Review of Thompson & Thompson’s Genetics and Genomics in Medicine, 9th edition (Elsevier).
A study from Johnson & Johnson Innovative Medicine, New Jersey, United States, report that patients with delayed genetic testing may incur significantly higher healthcare costs… Read More »Johnson & Johnson study reports the economic value of early genetic testing in inherited retinal dystrophies diagnosis.
Clinical researchers based in Oregon Health and Science University (OHSU), Portland and the Ocular Genomics Institute, Mass Eye and Ear, Harvard University, have published the… Read More »CRISPR experimental treatment on a Phase 1/2 study for LCA10 patients report meaningful improvements.
Researchers at the RIKEN BioResource Research Center, Kyoto, Japan, have reported that retinal organoids, derived from patients’ induced pluripotent stem cells (iPSCs) with a EYS… Read More »Retinal dystrophy caused by EYS dysfunction in retinal organoids shows significant phototoxicity from RIKEN research.
Dear EURETINA Members, A very warm welcome to the May 10th, 2024 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue… Read More »May 10th, 2024 “EURETINA-Brief”© Issue No. 291
A US company, LumiThera Inc., based in Seattle, WA, has announced a multi-centre clinical registry study to enroll up to 1,000 AMD patients with their… Read More »LumiThera Inc. have announced a multi-centre registry (“EUROLIGHT”) for their photo-biomodulation (PBM) treatment of dry AMD across up to 20 European centres.
A review from the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has reported that “orphan designations” (OD) on inherited retinal… Read More »The EMA Committee for Orphan Medicinal Products (COMP) propose a new approach to Orphan Designations (OD) on inherited retinal degenerations (IRDs).
